Axolotl Biologix

www.axobio.com

Axolotl Biologix is focused on research and collaboration through partnerships with top universities and hospitals to uncover optimal enablement of the body’s own cells and tissues to improve quality of life for people around the world.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

news image

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

news image

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

news image

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More

MedTech

BIOTECH START-UP AANIKA BIOSCIENCES LANDS INITIAL $12M FUNDING FOR CUTTING-EDGE FOOD TRACING TECHNOLOGY

Aanika Biosciences | December 01, 2021

news image

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accurac...

Read More
news image

Industrial Impact

PDS BIOTECH ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING WITH THE FDA AND PREPARATION FOR THE REGISTRATIONAL TRIAL

PDS Biotechnology | October 04, 2022

PDS Biotechnology Corporation a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, today announced that it has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for PDS0101 in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® for the treatment of unresectable, recurrent/metastatic human papilloma virus 16-positive head and neck squamous cell carcinoma. Read More

news image

Medical

BIOCYTOGEN ENTERS INTO BISPECIFIC ANTIBODY DRUG CONJUGATE AGREEMENT WITH RADIANCE BIOPHARMA

Biocytogen | January 15, 2024

Biocytogen Pharmaceuticals Co., Ltd. a global biotech company focusing on the discovery of novel antibody therapeutics, announces that it has entered into an Exclusive Option and License Agreement with Radiance Biopharma Inc. a biotechnology company specializing in developing next generation Antibody Drug Conjugates. The agreement grants Radiance an option to license from Biocytogen a first-in-class fully human anti-HER2/TROP2 bispecific antibody-drug conjugate (BsADC) for thera...

Read More
news image

Cell and Gene Therapy

SOLVIAS TO PERFORM RELEASE TESTING ON WORLD'S FIRST CRISPR-BASED GENE-EDITING THERAPY

Solvias | January 23, 2024

Solvias, a global provider of chemistry, manufacturing, and control (CMC) analytics, announced that it will perform analytical release testing services on the world's first CRISPR/Cas9 genome-edited cell therapy. The company has signed a long-term agreement with Vertex Pharmaceuticals for CASGEVY™ (exagamglogene autotemcel or exa-cel) which received U.S. Food & Drug Administration (FDA) approval for the treatment of sickle cell disease (SCD) in patients 12 years and older wit...

Read More
news image

MedTech

BIOTECH START-UP AANIKA BIOSCIENCES LANDS INITIAL $12M FUNDING FOR CUTTING-EDGE FOOD TRACING TECHNOLOGY

Aanika Biosciences | December 01, 2021

Biotech start-up Aanika Biosciences today announced the initial closing of its $12 million Series A round, led by Jon Cholak of Adit Ventures along with existing investors Draper Associates and SOSV. The investment will help scale the company’s food tracing technology platform, advance research and expand its Brooklyn food safety and manufacturing facility to approximately 30,000 square feet. Aanika's proprietary technology is designed to accelerate the speed and accurac...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us